BioSpace News Archive

According to the report, the global bone growth stimulators market was valued at US$ 1.32 Bn in 2018 and is projected to expand at a CAGR of 5.2% from 2019 to 2027.

Fact.MR – A Market Research and Competitive Intelligence Provider: According to Fact.MR analysis, the global spine devices market size was valued at US$ 11 Bn in 2020 and is projected to reach around US$ 17 Bn by 2031.

According to the report, the global animal drug compounding market was valued at US$ 1.1 Bn in 2019 and is projected to expand at a moderate CAGR from 2020 to 2030.

Saniona achieved orphan drug designation (ODD) from the FDA for Tesomet for the treatment of hypothalamic obesity (HO).

Medivir AB announces that results from the investigator-initiated phase II clinical study in patients with squamous cell carcinoma has been published in JAMA Dermatology by Kilgour, JM et al.

Generate Biomedicines, whose machine learning-powered Generative Biology platform can rapidly invent new drugs across a wide range of protein modalities and previously undiscoverable protein therapeutics, announced it has raised $370 Million in a Series B financing to advance the development of its novel drug generation platform.

Nordic Nanovector ASA, a clinical stage biotechnology company developing targeted radiopharmaceuticals to extend and improve the lives of patients with haematological cancers, will host an R&D Day on Tuesday, 30 November 2021 starting at 14:00 CET/ 13:00 GMT/ 08:00 ET.

Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, announced new interim data published from the large multi-center observational registry study INSIGHT utilizing its novel predictive and prognostic blood-based host immune classifier to stratify Immune checkpoint inhibition treatment response in patients with advanced non-small cell lung cancer.

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), today reports its financial results for the quarter ended September 30, 2021 and provides a corporate update.

ESSA Pharma Inc. (“ESSA”, or the “Company”) (NASDAQ: EPIX), today provided a corporate update and reported financial results for the fiscal year ended September 30, 2021.